Background: Vernal keratoconjunctivitis (VKC) is a chronic inflammatory eye condition predominantly affecting children. Despite its varied clinical manifestations, VKC poses challenges in diagnosis and management because of its multifactorial nature, potentially involving allergic sensitization and comorbidities.
Objective: The purpose of this study was to comprehensively assess VKC, focusing on the possible effect of allergic sensitization on the clinical form, severity, and quality of life of pediatric patients with VKC.
Methods: In this retrospective study, encompassing 248 children aged 5 to 12 diagnosed with VKC, clinical data, ophthalmologic assessments, and quality-of-life metrics were systematically collected. Patients were divided into sensitized and nonsensitized groups according to allergy investigations. Comprehensive evaluations included clinical history, symptom scoring, Bonini grading for severity, allergen tests, blood examinations, and ophthalmologic examinations.
Results: Among the enrolled patients, a prevalence of nonsensitized cases (56%) emerged. Both sensitized and nonsensitized groups displayed similar demographic profiles and clinical forms of VKC. A significantly higher occurrence of rhinitis and asthma was observed in the sensitized group. No significant differences were found in ophthalmologic and hematologic parameters between the 2 groups. Despite this, sensitized patients exhibited a significantly higher impact on quality of life, as indicated by QUICK questionnaire scores.
Conclusion: The study underscores the importance of comprehensive allergy assessments during VKC diagnosis, suggesting potential associations between sensitization and atopic comorbidities impacting patients' quality of life. Future investigations into environmental factors, specific allergens, and treatment response are pivotal for a holistic understanding of VKC's implications for pediatric patients' well-being.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11889350 | PMC |
http://dx.doi.org/10.1016/j.jacig.2025.100421 | DOI Listing |
J Cutan Med Surg
March 2025
Division of Dermatology, Department of Medicine, Queen's University, Kingston, ON, Canada.
Background: For optimal control of atopic dermatitis (AD), patient education is essential to complement traditional therapy. Patient education has proven to benefit AD outcomes, but previous methods of delivery are costly and time-consuming.
Objective: To assess the effectiveness of a one-page pictorial education tool at improving AD quality of life (QoL) and disease severity.
J Cutan Med Surg
March 2025
Division of Dermatology, University of Alberta, Edmonton, AB, Canada.
Calcinosis cutis, characterized by the pathological deposition of insoluble calcium salts in the skin, is associated with several disease entities, particularly autoimmune conditions such as scleroderma and dermatomyositis. Lesions of calcinosis are often painful, prone to ulceration, and significantly impair quality of life. Despite the clinical impact, no effective treatments have been established to date, making prevention of this condition a critical priority.
View Article and Find Full Text PDFJAMA Cardiol
March 2025
Department of Cardiovascular Medicine and Section on Geriatrics and Gerontology, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
Importance: Excess body fat plays a pivotal role in the pathogenesis of heart failure with preserved ejection fraction (HFpEF). HU6 is a novel, controlled metabolic accelerator that enhances mitochondrial uncoupling resulting in increased metabolism and fat-specific weight loss.
Objective: To assess efficacy and safety of HU6 in reducing body weight, improving peak volume of oxygen consumption (VO2) and body composition among patients with obesity-related HFpEF.
Curr Opin Support Palliat Care
March 2025
Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
Purpose Of Review: Two widely validated health-related quality of life (HR-QoL) tools, specifically designed for patients with advanced cancer, are the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 15 Palliative Care (EORTC QLQ-C15-PAL) and the Functional Assessment of Chronic Illness Therapy-Palliative (FACIT-Pal-14). This systematic review aims to evaluate the use of EORTC QLQ-C15-PAL and FACIT-Pal-14 in prospective studies in patients with advanced cancer, focusing on study types, clinical settings, additional HR-QoL tools used, and completion rates.
Recent Findings: Sixty studies were included in the analysis.
JAMA Netw Open
March 2025
Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!